{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T23:14:32Z","timestamp":1767395672976},"reference-count":25,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.3892\/or.2013.2948","type":"journal-article","created":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T08:29:44Z","timestamp":1388392184000},"page":"1109-1115","source":"Crossref","is-referenced-by-count":11,"title":["Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma"],"prefix":"10.3892","volume":"31","author":[{"given":"MAKIO","family":"MORIYA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TADAAKI","family":"YAMADA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASAYA","family":"TAMURA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DAISUKE","family":"ISHIKAWA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MIR ALIREZA","family":"HODA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ISAO","family":"MATSUMOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WALTER","family":"KLEPETKO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAKOTO","family":"ODA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SEIJI","family":"YANO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GO","family":"WATANABE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2013,12,30]]},"reference":[{"key":"key20180107222227_b1-or-31-03-1109","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.1996.14.3.1007","article-title":"Chemotherapy in malignant pleural mesothelioma. A review","volume":"14","author":"Ong","year":"1996","journal-title":"J Clin Oncol"},{"key":"key20180107222227_b2-or-31-03-1109","doi-asserted-by":"crossref","first-page":"373S","DOI":"10.1378\/chest.103.4_Supplement.373S","article-title":"Natural history and epidemiology of malignant mesothelioma","volume":"103","author":"Antman","year":"1993","journal-title":"Chest"},{"key":"key20180107222227_b3-or-31-03-1109","doi-asserted-by":"crossref","first-page":"332S","DOI":"10.1378\/chest.107.6_Supplement.332S","article-title":"Current approach to malignant mesothelioma of the pleura","volume":"107","author":"Aisner","year":"1995","journal-title":"Chest"},{"key":"key20180107222227_b4-or-31-03-1109","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"key20180107222227_b5-or-31-03-1109","first-page":"3581","article-title":"Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells","volume":"59","author":"Grewe","year":"1999","journal-title":"Cancer Res"},{"key":"key20180107222227_b6-or-31-03-1109","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","article-title":"Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus","volume":"66","author":"Del Bufalo","year":"2006","journal-title":"Cancer Res"},{"key":"key20180107222227_b7-or-31-03-1109","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"key20180107222227_b8-or-31-03-1109","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1200\/JCO.2005.66.130","article-title":"Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107222227_b9-or-31-03-1109","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtcvs.2009.06.027","article-title":"Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma","volume":"5","author":"Hartman","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"key20180107222227_b10-or-31-03-1109","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/JTO.0b013e31820e1a25","article-title":"Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy","volume":"6","author":"Hoda","year":"2011","journal-title":"J Thorac Oncol"},{"key":"key20180107222227_b11-or-31-03-1109","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1182\/blood-2004-03-1153","article-title":"In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model","volume":"15","author":"Frost","year":"2004","journal-title":"Blood"},{"key":"key20180107222227_b12-or-31-03-1109","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0022-1759(84)90190-X","article-title":"Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines","volume":"70","author":"Green","year":"1984","journal-title":"J Immunol Methods"},{"key":"key20180107222227_b13-or-31-03-1109","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/modpathol.2009.104","article-title":"EGFR-dependent and independent activation of Akt\/mTOR cascade in bone and soft tissue tumors","volume":"22","author":"Dobashi","year":"2009","journal-title":"Mod Pathol"},{"key":"key20180107222227_b14-or-31-03-1109","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","article-title":"Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study","volume":"23","author":"Galanis","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107222227_b15-or-31-03-1109","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1093\/emboj\/16.12.3693","article-title":"Rapamycin suppresses 5\u2032TOP mRNA translation through inhibition of p70s6k","volume":"16","author":"Jefferies","year":"1997","journal-title":"EMBO J"},{"key":"key20180107222227_b16-or-31-03-1109","first-page":"763","article-title":"mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma","volume":"25","author":"Schedel","year":"2011","journal-title":"Oncol Rep"},{"key":"key20180107222227_b17-or-31-03-1109","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107222227_b18-or-31-03-1109","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(94)90187-2","article-title":"The implications of angiogenesis for the biology and therapy of cancer metastasis","volume":"79","author":"Fidler","year":"1994","journal-title":"Cell"},{"key":"key20180107222227_b19-or-31-03-1109","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00006676-200208000-00002","article-title":"High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas","volume":"25","author":"Niedergethmann","year":"2002","journal-title":"Pancreas"},{"key":"key20180107222227_b20-or-31-03-1109","first-page":"3964","article-title":"Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer","volume":"55","author":"Takahashi","year":"1995","journal-title":"Cancer Res"},{"key":"key20180107222227_b21-or-31-03-1109","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0065-230X(06)97011-0","article-title":"PDGF receptors as targets in tumor treatment","volume":"97","author":"Ostman","year":"2007","journal-title":"Adv Cancer Res"},{"key":"key20180107222227_b22-or-31-03-1109","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"key":"key20180107222227_b23-or-31-03-1109","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2004-09-3540","article-title":"Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF","volume":"105","author":"Guba","year":"2005","journal-title":"Blood"},{"key":"key20180107222227_b24-or-31-03-1109","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1158\/1078-0432.CCR-07-0501","article-title":"The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107222227_b25-or-31-03-1109","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1158\/1078-0432.CCR-09-1980","article-title":"E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles","volume":"15","author":"Ikuta","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2948\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T22:30:06Z","timestamp":1515364206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,30]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,12,30]]},"published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.3892\/or.2013.2948"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2948","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,30]]}}}